ORIC Pharmaceuticals Appoints Chief Scientific Officer

ORIC Pharmaceuticals has appointed Lori Friedman, PhD, Chief Scientific Officer. Dr. Friedman will serve on the executive leadership team and lead ORIC's research and preclinical development efforts.
 
Dr. Friedman brings to ORIC over 20 years of experience in cancer research, including her 15-year career at Genentech, she was most recently head of translational oncology for Genentech Research and Early Development (gRED), where her team advanced more than 20 programs into clinical development. 
 
"We are thrilled to continue attracting top talent to ORIC's leadership team," said Jacob Chacko, MD, Chief Executive Officer. "Lori has a multi-decade record of leadership in oncology drug discovery and translation, including identifying and advancing multiple novel programs into the clinic that eventually achieved regulatory approval and commercialization. Lori's scientific acumen, leadership abilities and ability to collaborate closely on clinical development plans will be critical to continuing to advance and expand ORIC's pipeline."

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com